1 / 16

Richard Carter Head of Industry Sponsorship Department of Health London

Richard Carter Head of Industry Sponsorship Department of Health London. Presentation. Co-operation of public authorities and industry: why is it necessary to work together? The UK experience. The DH role in co-ordinating policy Our aim and why we do this How we go about it

ketan
Download Presentation

Richard Carter Head of Industry Sponsorship Department of Health London

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript

  1. Richard CarterHead of Industry SponsorshipDepartment of HealthLondon

  2. Presentation Co-operation of public authorities and industry: why is it necessary to work together? The UK experience

  3. The DH role in co-ordinating policy Our aim and why we do this How we go about it - Pharmaceuticals - Medical technology Characteristics of the relationship Outline of the presentation

  4. Our aim: The Government's strategy is to build on the UK’s reputation as being a leader in life sciences, and to work with both industries to improve the environment for them to continue to innovate.

  5. Why do we do this? • Importance of these industries to the economy of the UK • Vital role of each sector in supporting Government’s health goals and policies • Importance of innovation to health care reform

  6. Pharmaceutical Industry Invests over £3bn annually in R&D in the UK £12bn of medicines exported from the UK annually 68,000 directly employed by the pharmaceutical industry 16 of the worlds top-selling 75 medicines discovered in the UK Medical technology Annual output is in the region of £4bn including £2.2bn to the NHS Exports are about £2bn 55,000 directly employed by the medical technology industry Pharmaceutical & Medical Technology sectors in the UK

  7. How do we go about it? – Pharmaceuticals • History of the relationship is long • Since 1999 more systematic architecture of engagement • 1999-2001 PICTF • 2001-present MISG • MISG - industry side membership global, government side ministers and top officials • Meets twice a year • Joint consideration of strategic issues of common interest, e.g. science education

  8. Close Dialogue & Partnership with Industry-MISG & Long Term Leadership Strategy Ministerial Industry Strategy Group (MISG) MISG has overseen the development of the Long Term Leadership Strategy for Medicines (LTLS) which is designed to: • secure the provision of safe and effective medicines for patients; • maintain and strengthen the UK pharmaceutical industry within Europe; • and to advance healthcare innovation in the UK.

  9. Close Dialogue & Partnership with Industry- MISG - Long Term Leadership Strategy Three workstreams have reported on their conclusions: • Partnership Working Group: Dealing with the industry’s relationships with the NHS in England and with uptake of cost effective medicines • European Working Group: Improving the business and technology environment for the pharmaceutical industry in Europe • Regulatory Working Group: Developing the regulatory environment in the UK and Europe so as better to serve needs of all stakeholders

  10. Pharmaceuticals - LTLS Report February 2007

  11. How do we go about it – Medical Technology • Shorter history of joint engagement • Healthcare Industries Task Force (HITF) a year long joint Initiative was set up in 2003 • Beginning of an important dialogue between Government and the sector • Implementation of its key outputs from 2004 • New strategic group – Ministerial Medical Technology Strategy Group – set up to take forward recommendations • Will meet twice a year • Will consider strategic issues of common interest, e.g. small business support in this sector, innovation

  12. Key outputs of HITF • Integration of technology evaluation into procurement - Centre for Evidence-based Purchasing (CEP) • Establishment of a National Innovation Centre (NIC) • Strengthened R&D environment for medical technologies • Streamlined procurement process • Continuing shared strategic agenda and architecture within which to pursue it

  13. Medical Technology - Published Reports 2004 and 2007 Further details are available on: www.advisorybodies.doh.gov.uk/hitf

  14. Characteristics of the relationships • Well established long term engagement • Very senior representation from both sides on the two joint government/industry groups • Genuine interest on both sides in holding constructive dialogue at strategic level • Openness and transparency • Ability to disagree without rupturing the connection • Strong horizontal working across relevant government departments

  15. The UK Governmentpharmaceutical & medical technologyIndustry linkages: a schematic overview • Pharmaceuticals FCO/UKTI Inward investment DIUS Skills • Medical Technology DFID Access to medicines NHSIII/NIC HO Animal rights legislation DBERR Science base DH Co-ordination & policy/ Purchaser/NHS NHS PASA Procurement, device evaluation HMT Tax incentives/ Science strategy MHRA EU medicines/device legislation NICE Appraisals of New technologies UKCRC Translational Clinical research OSCHR Health research

  16. KeyMessages • Government committed to a strong relationship with industry • Both parties to the relationship benefit • Working in partnership wherever possible has enabled us to achieve many shared goals

More Related